346 related articles for article (PubMed ID: 34804845)
1. Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature review.
Koshkin VS; Osbourne AS; Grivas P
Transl Androl Urol; 2021 Oct; 10(10):4022-4035. PubMed ID: 34804845
[TBL] [Abstract][Full Text] [Related]
2. The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
Lavoie JM; Sridhar SS; Ong M; North S; Alimohamed N; McLeod D; Eigl BJ
Oncologist; 2021 Aug; 26(8):e1381-e1394. PubMed ID: 34028134
[TBL] [Abstract][Full Text] [Related]
3. Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.
Domb C; Garcia JA; Barata PC; Mendiratta P; Rao S; Brown JR
Ther Adv Urol; 2024; 16():17562872241249073. PubMed ID: 38779496
[TBL] [Abstract][Full Text] [Related]
4. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
Bednova O; Leyton JV
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
[TBL] [Abstract][Full Text] [Related]
6. Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin.
Shafique MA; Haseeb A; Siddiq MA; Mussarat A; Rangwala HS; Mustafa MS
Cancer Manag Res; 2023; 15():699-706. PubMed ID: 37485038
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Landscape Beyond Immunotherapy in Advanced Urothelial Carcinoma: Moving Past the Checkpoint.
Tripathi A; MacDougall K; Sonpavde GP
Drugs; 2022 Nov; 82(17):1649-1662. PubMed ID: 36441503
[TBL] [Abstract][Full Text] [Related]
8. The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer.
Hanna KS; Larson S; Nguyen J; Boudreau J; Bulin J; Rolf M
Am J Health Syst Pharm; 2022 Apr; 79(8):629-635. PubMed ID: 34864835
[TBL] [Abstract][Full Text] [Related]
9. Enfortumab Vedotin in urothelial cancer.
Alt M; Stecca C; Tobin S; Jiang DM; Sridhar SS
Ther Adv Urol; 2020; 12():1756287220980192. PubMed ID: 33447264
[TBL] [Abstract][Full Text] [Related]
10. Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy.
Tassinari E; Mollica V; Nuvola G; Marchetti A; Rosellini M; Massari F
Cancer Manag Res; 2022; 14():1945-1960. PubMed ID: 35720644
[TBL] [Abstract][Full Text] [Related]
11. Targeted and immunotherapy for the management of advanced urothelial carcinoma of the bladder.
Cersosimo RJ
Am J Health Syst Pharm; 2024 Apr; ():. PubMed ID: 38679913
[TBL] [Abstract][Full Text] [Related]
12. Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma.
Hui G; Stefanoudakis D; Zektser Y; Isaacs DJ; Hannigan C; Pantuck AJ; Drakaki A
Curr Oncol; 2023 Aug; 30(8):7398-7411. PubMed ID: 37623017
[TBL] [Abstract][Full Text] [Related]
13. The evolving treatment landscape of metastatic urothelial cancer.
Roviello G; Santoni M; Sonpavde GP; Catalano M
Nat Rev Urol; 2024 May; ():. PubMed ID: 38702396
[TBL] [Abstract][Full Text] [Related]
14. Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review.
Bantounou MA; Plascevic J; MacDonald L; Wong MC; O'Connell N; Galley HF
Curr Urol; 2023 Dec; 17(4):271-279. PubMed ID: 37994340
[TBL] [Abstract][Full Text] [Related]
15. Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives.
Iacovelli R; Cicala CM; Ciccarese C; Sacco E; Racioppi M; Bassi PF; Tortora G
Urologia; 2023 Feb; 90(1):3-10. PubMed ID: 36537831
[TBL] [Abstract][Full Text] [Related]
16. Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma.
Sayegh N; Tripathi N; Agarwal N; Swami U
Onco Targets Ther; 2022; 15():1047-1055. PubMed ID: 36186154
[TBL] [Abstract][Full Text] [Related]
17. Antibody-Drug Conjugates in Uro-Oncology.
Sigorski D; Różanowski P; Iżycka-Świeszewska E; Wiktorska K
Target Oncol; 2022 May; 17(3):203-221. PubMed ID: 35567672
[TBL] [Abstract][Full Text] [Related]
18. Erdafitinib for the treatment of metastatic bladder cancer.
Montazeri K; Bellmunt J
Expert Rev Clin Pharmacol; 2020 Jan; 13(1):1-6. PubMed ID: 31810398
[No Abstract] [Full Text] [Related]
19. Enfortumab vedotin - next game-changer in urothelial cancer.
Maas M; Stühler V; Walz S; Stenzl A; Bedke J
Expert Opin Biol Ther; 2021 Jul; 21(7):801-809. PubMed ID: 33325754
[No Abstract] [Full Text] [Related]
20. Progress in systemic therapy for advanced-stage urothelial carcinoma.
Nadal R; Valderrama BP; Bellmunt J
Nat Rev Clin Oncol; 2024 Jan; 21(1):8-27. PubMed ID: 37945764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
